TOPOREK MICHAEL 4/A

What Happened

• Michael Toporek, a director of Capstone Holding Corp. (CAPS), was granted 356,250 shares of common stock on March 30, 2026 as restricted stock awards (no consideration). The Form 4/A filed July 24, 2026 amends an earlier filing to correct that these were common shares (not RSUs) and to fix the vesting schedule. No per‑share price or total dollar value is reported.

Key Details

• Transaction date: March 30, 2026. Amended Form 4/A filed: July 24, 2026.
• Grant: 356,250 shares of common stock granted for no consideration (reported as an award, code A).
• Vesting: awards vest in full only upon the Reporting Person’s death or disability, removal from the board other than for Cause, or failure to be re‑elected; forfeited if the director voluntarily resigns before a vesting event (per footnote).
• Correction: amendment clarifies the instruments are common stock (not RSUs) and corrects the vesting schedule (footnote F1).
• Ownership note: filing excludes 121,774 shares controlled by Toporek through BP Peptides, LLC (footnote F3). The filing does not state total beneficial ownership after the grant.
• Timeliness: this is an amended filing submitted nearly four months after the grant date; the delay reduces prompt public disclosure.

Context

• Restricted stock awards (RSAs) are not an open‑market purchase or sale and typically cannot be sold until they vest; these particular awards vest only on specific events, so they may not provide immediate liquidity or indicate ongoing buying/selling intent.
• The amendment improves accuracy of public records by correcting the security type and vesting terms. Late filings can limit timely market transparency but do not by themselves indicate improper trading.